ABSTRACT
During the COVID-19 pandemic, construction accidents in the United States (US) dropped dramatically compared to previous years. This research uses Saunders’ research onion approach to conduct a deep and systematic analysis of pre- and post-COVID-19 data to understand this phenomenon. The proposed research framework examines safety and prevention measures implemented by the US government, using data collected from various US government agencies, including the Occupational Safety and Health Administration (OSHA), Centers for Disease Control and Prevention (CDC), and US Bureau of Labor Statistics. COVID-19’s effects on construction site health and safety were analyzed and ranked in order of efficacy in a hierarchy of control, and findings reveal a number of safety measures that can potentially be implemented to promote improved construction safety even after COVID-19 is over.
ABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global threat to human health. Using a multidisciplinary approach, we identified and validated the hepatitis C virus (HCV) protease inhibitor simeprevir as an especially promising repurposable drug for treating COVID-19. Simeprevir potently reduces SARS-CoV-2 viral load by multiple orders of magnitude and synergizes with remdesivir in vitro. Mechanistically, we showed that simeprevir inhibits the main protease (Mpro) and unexpectedly the RNA-dependent RNA polymerase (RdRp). Our results thus reveal the viral protein targets of simeprevir, and provide preclinical rationale for the combination of simeprevir and remdesivir for the pharmacological management of COVID-19 patients. One Sentence SummaryDiscovery of simeprevir as a potent suppressor of SARS-CoV-2 viral replication that synergizes with remdesivir.